文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

人工肝支持系统有效清除严重肝衰竭患者循环中的免疫抑制性胆汁酸:一项概念验证研究

Artificial Liver Support Effectively Removes Immunosuppressive Bile Acids From Circulation in Patients With Severe Liver Failure: A Proof of Concept Study.
PubMed 文献 · Crit Care Explor · 2026-06-08
一句话结论在严重肝衰竭患者中,OPAL与MARS均能显著清除胆红素和胆汁酸,OPAL在清除蛋白结合性亲脂胆汁酸和恢复白蛋白功能上优于MARS。

这项多中心概念验证研究纳入符合SOFA肝亚评分定义(胆红素>12 mg/dL)的严重肝衰竭患者,随机接受一次8小时MARS或OPAL治疗,次日交叉至另一治疗。两种系统均显著清除胆红素及总/单个胆汁酸;OPAL在清除蛋白结合性亲脂胆汁酸和恢复白蛋白功能(白蛋白结合容量、解毒效率、结合效率)方面优于MARS。循环胆汁酸诱导的TGR5激活在OPAL后降低60%,MARS后降低39%(中位数,p=0.051)。作者认为人工肝支持系统能有效清除免疫抑制性胆汁酸,但胆汁酸降低的临床意义仍需进一步研究。

要点

  • 严重肝衰竭定义为SOFA肝亚评分即胆红素>12 mg/dL,此类患者随机接受一次8小时MARS或OPAL治疗,次日交叉。
  • OPAL与MARS均能显著清除循环中的胆红素以及单个和总胆汁酸。
  • OPAL在清除蛋白结合性亲脂胆汁酸和恢复白蛋白功能(白蛋白结合容量、解毒效率、结合效率)方面优于MARS。
  • 循环胆汁酸诱导的TGR5激活在OPAL后降低60%,MARS后降低39%(中位数,p=0.051)。
  • 作者认为人工肝支持系统能有效清除免疫抑制性胆汁酸,但其临床意义仍需进一步研究。

适用人群与场景

  • 严重肝衰竭患者,定义依据序贯器官衰竭评估(SOFA)肝亚评分,即胆红素>12 mg/dL。
  • 研究在德国耶拿大学医院、乌尔姆大学医院和明斯特大学医院进行。

诊断标准与关键阈值

  • 严重肝衰竭定义:SOFA肝亚评分,即胆红素>12 mg/dL。

处置流程与药物剂量

  • 患者随机接受一次8小时的MARS或OPAL治疗,次日交叉至另一种治疗。

研究设计与关键结果

  • 研究设计:概念验证研究,多中心研究,在德国三家大学医院进行。
  • 干预与对照:严重肝衰竭患者随机接受一次8小时MARS或OPAL治疗,次日交叉至另一治疗。
  • 主要终点结果:OPAL与MARS均显著清除循环中的胆红素以及单个和总胆汁酸;OPAL在清除蛋白结合性亲脂胆汁酸和恢复白蛋白功能(白蛋白结合容量、解毒效率、结合效率)方面优于MARS。
  • 循环胆汁酸诱导的TGR5激活在OPAL后降低60%,MARS后降低39%(中位数,p=0.051)。

证据类型、等级与局限

  • 证据类型:概念验证研究,多中心研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为人工肝支持系统能有效清除免疫抑制性胆汁酸,但胆汁酸降低的临床意义仍需进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Bile acids that induce immunosuppression through activation of the Takeda G protein-coupled receptor 5 (TGR5) have recently been identified in the circulation of patients with liver failure and sepsis. These bile acids are associated with increased susceptibility to infection and a high short-term mortality. Furthermore, TGR5 activation by bile acids has been implicated in the development of pruritus. However, therapies targeting TGR5-activating bile acids in patients have not yet been reported. This study investigates the effects of two artificial liver support systems, the Molecular Adsorbent Recirculating System (MARS) and the open albumin dialysis (OPAL).

DESIGN: Proof of concept study, multicenter study.

SETTING: University Hospital Jena, University Hospital Ulm, and University Hospital Münster, Germany.

PATIENTS: Patients with severe liver failure, as defined by the Sequential Organ Failure Assessment hepatic sub-score (i.e., bilirubin > 12 mg/dL).

INTERVENTIONS: Patients with severe liver failure were randomized to receive one session of MARS or OPAL for 8 hours, followed by crossover to the other treatment on the next day.

MEASUREMENTS AND MAIN RESULTS: Bilirubin, circulating total and individual bile acids, albumin function, and TGR5 activation induced by circulating bile acids were assessed before and after each treatment session. Both OPAL and MARS significantly removed bilirubin, as well as individual and total bile acids from circulation. OPAL was superior to MARS in removing protein-bound lipophilic bile acids and restoring patients' albumin function (i.e., albumin-binding capacity, detoxification efficiency, and binding efficiency). TGR5 activation induced by circulating bile acids was reduced by 60% with OPAL compared with 39% with MARS (median values, p = 0.051).

CONCLUSIONS: Artificial liver support systems effectively remove immunosuppressive bile acids from circulation. The clinical implications of bile acid reduction, however, require further study.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Leonhardt J, Schmidt HH, Koball S, et al. Artificial Liver Support Effectively Removes Immunosuppressive Bile Acids From Circulation in Patients With Severe Liver Failure: A Proof of Concept Study. Crit Care Explor. 2026. PMID: 42249543. doi:10.1097/CCE.0000000000001419

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。